As previously discussed, TM6SF2 gene knockout, inhibition of MDM2–ApoB interaction, HNF4α, GLS1 inhibition, and mTORC1 activation on VLDL lipidization have shown great potential for reducing steatosis by regulating VLDL to affect MASLD. This evidence concerns the gene TM6SF2 and steatosis.